{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        976, 
        990
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        727, 
        750
      ]
    }
  ], 
  "Comments Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1644, 
        1664
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        869, 
        896
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        457, 
        486
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1424, 
        1459
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Steven,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1560, 
        1586
      ]
    }
  ], 
  "Neoplasm Descriptive Grade (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20171128_CDC_B1B2_4,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        954, 
        975
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Gemma,Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        908, 
        923
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PathSys|ParkRidge Medical Center^44D0705108^CLIA|eMARCPlus|TN Cancer Registry|20170925000151||ORU^R01^ORU_R01|201709250001510001|P|2.5.1|TN||||||||VOL_V_40_ORU_R01-CCR1^NAACCR_CP\nOBR|1||17-PK-005814^PathSys^44D0705108^CLIA|11529-5^SURGICAL PATH REPORT^LN|||20170913000000|||||||20170913000000|&Colon, Biopsy|1306036447^ ^^M^^^MD^^CMS^D^^^NPI||||||20170915000000|||F||||||C18.5^Malignant neoplasm of splenic flexure^I10|1083680706&&&&&&&&CMS\n\n\n\n\n\n\n\nPath report.gross description\n\nThe specimen is received in formalin identified by the requisition and container as \", cold biopsy mass splenic flexure.\" Four portions of soft tan-gold tissue 0.3 to 0.4 cm in maximum dimension are submitted as received in cassette 1A.\n\n\nPath report.relevant Hx\n\nHistory - GI bleed, hematochezia, lipoma x2, likely malignant semi-circumferential mass ascending colon, fair prep\n\n\nPath report.final diagnosis\n\nBiopsies, splenic flexure, semi-circumferential mass:   Poorly differentiated adenocarcinoma.   (See comments.)   Malignant tumor CK7 negative.   Malignant tumor CK20 negative.   Malignant tumor CDX2 positive.   Malignant tumor chromogranin negative.   Malignant tumor synaptophysin negative.   Malignant tumor CD56 negative.   Malignant tumor MLH-1 LOSS of nuclear staining.   Malignant tumor MSH-2 intact nuclear staining.   Malignant tumor MSH-6 intact nuclear staining.   Malignant tumor PMS-2 LOSS of nuclear staining.\n\n\nPath report.microscopic examination\n\nMicroscopic examination supports the diagnosis as above. All control slides stain appropriately.\n\n\nPath report.site of origin\n\nCold biopsy semi-circumferential mass splenic flexure\n\n\nPath report.comments\n\nComments - The malignant tumor is histologically similar to that seen in the biopsies of a porta hepatis mass (17-PK-5532; 08/31/2017). The histologic features and immunoreactivity profile raise the possibility of a medullary carcinoma of the colon. Immunohistochemistry is performed with appropriate controls on block 1A for MLH-1, MSH-2, MSH-6, and PMS-2 to determine eligibility for pembrolizumab treatment for advanced solid malignancies. The results are as above. The patient's tumor is MMR-D by IHC and thus does meet eligibility criteria at this time. Consideration should be given to Genetic Counseling and further testing to rule out Lynch Syndrome. Reviewed by: LMP\n\n\n"
}